SARS-CoV-2 vaccines in development
Top Cited Papers
- 23 September 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 586 (7830), 516-527
- https://doi.org/10.1038/s41586-020-2798-3
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China and caused a coronavirus disease 2019 (COVID-19) pandemic. To mitigate the public health, economic and societal impacts of the virus, a vaccine is urgently needed. The development of SARS-CoV-2 vaccines was initiated in early January 2020 when the sequence of the virus became available and moved at record speed with one Phase I trial already starting in March 2020 and currently more than 180 vaccines in various stages of development. Phase I/II trial data is already available for several vaccine candidates and many have moved into Phase III trials. The data available so far suggests that effective and safe vaccines might become available within months rather than years.This publication has 104 references indexed in Scilit:
- High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009–2010 seasonVaccine, 2013
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Expression of Homing Receptors on IgA1 and IgA2 Plasmablasts in Blood Reflects Differential Distribution of IgA1 and IgA2 in Various Body FluidsClinical and Vaccine Immunology, 2010
- Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adultsVaccine, 2009
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathwayCell Research, 2008
- Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitroVaccine, 2007
- Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike VariantsPLoS Medicine, 2006
- Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult LifeThe Journal of Experimental Medicine, 2002